Company / Current Liabilities
CHINA PHARMA HOLDINGS, INC. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$7.4M
FY2025
5-year range
$5.0M / $12.7M
FY2021-FY2025
Trend
+47.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities returned to growth in FY2025 after 2 years of decline, reaching $7M.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of -8.3%.
Increased from $7M to $7M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -16.6%
- 5-Year CAGR
- -8.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -8.3%, indicating a declining trend.
- In FY2025, current liabilities increased 47.5% year-over-year.
- Peak current liabilities was recorded in FY2022.
- Lowest current liabilities in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.4M | +47.5% |
| FY2024 | $5.0M | -26.4% |
| FY2023 | $6.8M | -46.5% |
| FY2022 | $12.7M | +21.2% |
| FY2021 | $10.5M | -7.8% |
| FY2020 | $11.4M | +13.5% |
| FY2019 | $10.0M | -0.1% |
| FY2018 | $10.1M | +8.9% |
| FY2017 | $9.2M | -11.3% |
| FY2016 | $10.4M | -18.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026